Acquisitions (Details) $ in Millions	1 Months Ended	12 Months Ended
Sep. 30, 2018 USD ($) program	Dec. 31, 2018 USD ($)
Acquisitions
Number of gene therapy programs for neurologic LSDs developed \| program	10
Celenex
Acquisitions
Contingent consideration based on the achievement of certain milestones	$ 10.0
Contingent consideration based on the achievement of regulatory milestones	220.0
Maximum payment under contingent consideration	75.0
Research and development expense		$ 100.0
Celenex \| Nationwide Children's Hospital
Acquisitions
Contingent consideration based on the achievement of certain milestones	$ 7.8

Number Of Gene Therapy Programs For Neurologic LSDs Developed

No definition available.

Name:	fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped
Namespace Prefix:	fold_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Contingent On Development

+ References

No definition available.

+ Details

Name:	fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones

+ References

No definition available.

+ Details

Name:	fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years

+ References

No definition available.

+ Details

Name:	fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	fold_AssetAcquisitionAxis=fold_CelenexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=fold_NationwideChildrensHospitalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: